Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Organising pneumonia22.01.02.0080.000233%Not Available
Adverse reaction08.06.01.0180.000186%Not Available
Oral disorder07.05.01.005--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000252%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000839%
Acute kidney injury20.01.03.0160.006807%
Foetal growth restriction18.03.01.0020.000280%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000839%Not Available
Reversible cerebral vasoconstriction syndrome18.06.01.004; 17.08.02.014; 24.04.06.0260.000233%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.000559%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000233%Not Available
Intestinal angioedema23.04.01.019; 10.01.05.019; 07.08.03.0120.000140%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000373%
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.000093%Not Available
Diffuse vasculitis24.12.04.009; 10.02.02.0240.000186%Not Available
Epiglottic oedema22.04.02.0060.000140%Not Available
Hallucination, olfactory19.10.04.0050.000140%Not Available
Intervertebral disc displacement15.10.01.0060.000186%Not Available
Magnesium deficiency14.04.02.0030.000140%Not Available
Neonatal asphyxia22.11.02.006; 18.04.15.0050.000233%Not Available
Neonatal respiratory distress syndrome18.04.10.003; 22.11.02.0100.000186%Not Available
Obstructed labour18.07.01.0080.000093%Not Available
Pityriasis rubra pilaris23.03.08.0130.000392%Not Available
Placental insufficiency24.04.12.002; 18.05.02.0060.000280%Not Available
Small for dates baby18.04.02.0020.000186%Not Available
Thrombocytopenia neonatal18.04.03.005; 01.08.01.0100.000140%Not Available
Ureteric stenosis20.06.01.0100.000093%Not Available
Vulval cancer16.12.08.001; 21.08.03.0050.000326%Not Available
Oral dysaesthesia17.02.06.033; 07.05.05.0220.000093%
Retrognathia15.10.05.0080.000233%Not Available
The 21th Page    First    Pre   21 22 23    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene